Defecation

Current constipation medications don't provide relief for some patients with Chronic Idiopathic Constipation, per Gastroenterologist survey

Retrieved on: 
Tuesday, April 9, 2024
Adverse, Laxative, Gastrointestinal disease, Defecation, Patient, Human, American Journal, Weight loss, Constipation, News, Quality of life, Vibrant consonant, Hope, Invention, FDA

The survey of roughly 100 high-volume gastroenterology providers found that 74 percent of those interviewed are either unsure or positive that the medications they prescribe for patients with chronic constipation are not working.

Key Points: 
  • The survey of roughly 100 high-volume gastroenterology providers found that 74 percent of those interviewed are either unsure or positive that the medications they prescribe for patients with chronic constipation are not working.
  • Disrupting the U.S. $4.6 billion constipation treatment market, Vibrant Gastro’s first-in-class technology offers providers and patients with a new, non-pharmaceutical alternative to address this issue.
  • Patients track the progress of the treatment on their phone with an app to increase compliance, consistency and to monitor results.
  • A study presented at Digestive Disease Week in 2023 found significant symptomatic relief in patients and a substantially improved quality of life.

First Day Introduces Women's Good Gut - The World's 1st Women's Gummy 3-in-1 Pre+ Post+ Probiotic!

Retrieved on: 
Thursday, March 7, 2024
Skin, Probiotic, Woman, Absorption, Digestion, Bloating, Growth, Overalls, Postbiotic, First, Dentistry, Vagina, Defecation, Constipation, Immunity, Nutrient, Movement, Itch, Nutritional science, Ageing, Birth control

AUSTIN, Texas, March 7, 2024 /PRNewswire-PRWeb/ -- First Day, the brand trusted for its innovative line of multivitamins for kids, teens, women, and men, announced today the launch of a groundbreaking product: Women's Good Gut. The world's first tri-biotic designed specifically to address digestive, immune, and vaginal health concerns in women aged 18 and above. A 30-day supply of kiwi-flavored gummies, this product aims to empower women to take control of their gut health and overall well-being. Spearheaded by CEO and Founder, Alice Li, this revolutionary supplement marks a significant milestone in women's wellness.

Key Points: 
  • A 30-day supply of kiwi-flavored gummies, this product aims to empower women to take control of their gut health and overall well-being.
  • A 30-day supply of kiwi-flavored gummies, this product aims to empower women to take control of their gut health and overall well-being.
  • Women's Good Gut is now available for purchase on the First Day website ( www.firstday.com ), offering women a holistic approach to gut health and well-being.
  • Join the movement towards optimal wellness with Women's Good Gut from First Day.

2024 IBS Awareness Month: The IBS Dilemma

Retrieved on: 
Thursday, March 7, 2024
Gastroenterology, Anxiety, Mental health, MD, Education, Diarrhea, Irritable bowel syndrome, Friends, Quality of life, Bloating, BMS, Defecation, Constipation, Habit, Face, Fear, International Foundation, Feinberg School of Medicine, IBS, Depression, Nursing

MOUNT PLEASANT, S.C., March 7, 2024 /PRNewswire/ -- Irritable bowel syndrome (IBS) affects up to 5-10% of individuals worldwide, making it one of the most common gastrointestinal disorders. Although IBS does not shorten a person's life span, living with IBS presents a myriad of challenges that can significantly impact one's quality of life. From navigating social situations to managing work responsibilities, individuals with IBS constantly face dilemmas that others may not fully comprehend. This April, for IBS Awareness Month, IFFGD highlights how crucial it is to shed light on the profound dilemmas and challenges individuals living with this often-misunderstood condition may face.

Key Points: 
  • This April, for IBS Awareness Month, IFFGD highlights how crucial it is to shed light on the profound dilemmas and challenges individuals living with this often-misunderstood condition may face.
  • This year, help IFFGD and the community raise awareness, promote understanding, and offer compassion to those living with IBS.
  • You can also join IFFGD's awareness campaign by sharing information from the IBS Awareness Month Media Toolkit .
  • Learn more about IBS, visit www.aboutIBS.org or www.youandibs.org to learn about IBS through and animated video series.

Gut microbiome: meet Bilophila wadsworthia – a microbe that’s both friend and foe

Retrieved on: 
Friday, February 16, 2024
Hydrogen, Oxygen, Fungus, Smell, Partial pressure, Diet, Inflammation, News, Growth, Bile, Hydrogen sulfide, Meat, Cell, Defecation, Health, Irritable bowel syndrome, Bacteria, Virus, Appendicitis, Inflammatory bowel disease, Disease, Archaea, Fermentation, Colorectal cancer, Research, Sulfur

Hydrogen sulfide is the gas responsible for the rotten-egg odour that you come across near stagnant water and in drains.

Key Points: 
  • Hydrogen sulfide is the gas responsible for the rotten-egg odour that you come across near stagnant water and in drains.
  • Bilophila wadsworthia is one such species of these bacteria.
  • The bacteria that break down sulfur-containing organic matter and produce hydrogen sulfide are fittingly called sulfate-reducing bacteria.
  • Sulfate-reducing bacteria are an important part of the normal human gut microbiome, and small amounts of hydrogen sulfide are required in the human gut environment.
  • Bilophila wadsworthia was discovered in the 1980s, when it was found in people who had severe appendicitis.
  • The researchers found that it grew really well in bile, which is why the genus name is Bilophila (meaning bile loving).
  • Since then, research has associated Bilophila wadsworthia with negative effects in the gut.
  • It’s not clear how or why expansion of Bilophila wadsworthia can occur in the gut.


Jade Davies receives funding from UKRI via the BBSRC as part of the Norwich Research Park Doctoral Training Partnership (grant no. BB/M011216/1).

Herbal medicinal product: Plantaginis ovatae semenArray, C: ongoing call for scientific data

Retrieved on: 
Friday, February 16, 2024
Psyllium, Key, Inhalation, Committee, Monograph, Conjunctivitis, Inflammation, Pain, Bronchospasm, Anaphylaxis, Hemorrhoid, Human, Eye, Allergy, Date, Defecation, Risk, Seed, Mouth, Constipation, Safety, Stomach, Rectum, Plantago, Rhinitis, Patient, Medicine, Bleeding, Abdominal distension, Anal, Herbal medicine, Flatulence, Failure, Water

Herbal medicinal product: Plantaginis ovatae semenArray, C: ongoing call for scientific data

Key Points: 


Herbal medicinal product: Plantaginis ovatae semenArray, C: ongoing call for scientific data

Herbal medicinal product: Plantaginis ovatae seminis tegumentumArray, C: ongoing call for scientific data

Retrieved on: 
Friday, February 16, 2024
Key, Inhalation, Committee, Monograph, Diet, Conjunctivitis, Inflammation, Pain, Bronchospasm, Anaphylaxis, Hemorrhoid, Human, Eye, Allergy, Date, Defecation, Risk, Seed, Mouth, Constipation, Hypercholesterolemia, Safety, Irritable bowel syndrome, Stomach, Rectum, Rhinitis, Abdominal pain, Patient, Medicine, Disease, Bleeding, Abdominal distension, Anal, Herbal medicine, Flatulence, Failure, Water

Herbal medicinal product: Plantaginis ovatae seminis tegumentumArray, C: ongoing call for scientific data

Key Points: 


Herbal medicinal product: Plantaginis ovatae seminis tegumentumArray, C: ongoing call for scientific data

InventHelp Inventor Develops New Personal Care Glove (NPL-403)

Retrieved on: 
Monday, January 22, 2024
Defecation, Multimedia, Sale, Nursing, Skin, Bacteria, Suite, Hospital, DEPT, Airport

It can be used as an everyday germ free protected glove on any surface to be touched, not just in the bathroom."

Key Points: 
  • It can be used as an everyday germ free protected glove on any surface to be touched, not just in the bathroom."
  • The patent-pending invention provides an effective means of protecting a person's hand when wiping after defecation.
  • In doing so, it offers a barrier against fecal matter and the user's hand.
  • 22-NPL-403, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext.

Ironwood Announces Publication in The Lancet Gastroenterology & Hepatology of New Linaclotide Phase III Data in Children and Adolescents Aged 6-17 Years with Functional Constipation

Retrieved on: 
Tuesday, January 9, 2024
Research, Teens, Children, FDA, Clinical Trials, Biotechnology, Pharmaceutical, Consumer, Health, Science, Phase, Food, Constipation, Division, University of Miami, G.I., Pediatric gastroenterology, Medication, Ageing, Linaclotide, Defecation, SBM, University, Nutrition, Knowledge, Ironwood Pharmaceuticals, Functional constipation, Patient, The Lancet, Food and Drug Administration

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that new data from the Phase III study that evaluated linaclotide in children and adolescents aged 6-17 years with functional constipation were published in The Lancet Gastroenterology & Hepatology.

Key Points: 
  • Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that new data from the Phase III study that evaluated linaclotide in children and adolescents aged 6-17 years with functional constipation were published in The Lancet Gastroenterology & Hepatology.
  • Functional constipation in children is defined as a condition with hard, infrequent bowel movements that are often difficult or painful to pass1.
  • Linaclotide (marketed as LINZESS®) 72mcg is available in the U.S. for the treatment of functional constipation for pediatric patients aged 6-17 years old.
  • “The publication of these results in The Lancet Gastroenterology & Hepatology adds to the body of knowledge about linaclotide and helps close the unmet needs gap in pediatric patients ages 6- 17 with FC.”

Make Your New Year's Resolutions Last with Insights from Dr. Steven Gundry, Featuring Gundry MD Bio Complete 3 Supplement

Retrieved on: 
Friday, December 29, 2023
Fasting, Defecation, Metabolism, Habit, Nutritional science, Weight loss, Capsule, Probiotic, Steven Gundry, Health, Eating, Mitochondrion, Digestion, Energy, Gundry

LOS ANGELES, Dec. 29, 2023 /PRNewswire/ -- As the countdown to the new year begins, so does the tradition of setting resolutions. However, statistics show that by mid-February, many individuals find themselves falling off the wagon. Renowned health expert Dr. Steven Gundry suggests his approach to ensure your resolutions stick: make tiny changes to your routine that can easily evolve into lasting habits.

Key Points: 
  • Supercharge with Supplements: Dr. Gundry recommends incorporating supplements into your daily routine, with a particular emphasis on Gundry MD Bio Complete 3 .
  • Gundry MD Bio Complete 3 is a triple-pronged gut health powerhouse that contains a blend of probiotics, prebiotics, and postbiotics.
  • Dr. Gundry, the founder of Gundry MD, advises users to maintain a consistent intake of Gundry MD Bio Complete 3 for at least three months to fully appreciate its potential and achieve optimal outcomes.
  • Gundry MD Bio Complete 3 can be purchased on the Gundry MD site for the price of $69.95 for a 30-day supply with a 90-day purchase price guarantee.

Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome

Retrieved on: 
Monday, December 18, 2023
Conference, Aes, CS, Acromegaly, Diarrhea, FDA, Headache, Conference call, Carcinoid syndrome, SAN, Abdominal pain, Defecation, Pharmacokinetics, Flushing, ID, Webcast, Patient, Safety, Pharmaceutical industry

SAN DIEGO, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced positive initial findings from its ongoing open-label Phase 2 carcinoid syndrome (CS) study of paltusotine, an oral, once-daily investigational compound being developed for the treatment of acromegaly and CS.

Key Points: 
  • “We are very encouraged by these strong initial findings in our Phase 2 study of paltusotine in people with carcinoid syndrome,” said Scott Struthers, Ph.D., founder and chief executive officer of Crinetics.
  • “These initial results show the potential of paltusotine to significantly reduce both frequency and intensity of bowel movements and flushing, the key carcinoid syndrome symptoms.
  • Thirteen of the 15 participants (87%) who completed the randomized treatment phase enrolled in the long-term extension phase of the study.
  • Crinetics will hold a conference call and live webcast on Monday, December 18 at 5:00 p.m. Eastern Time to discuss the initial findings from the Phase 2 study.